GlassScriptPhysician profile
Amanda Beehler
NPI 1538308242
$1,864.72
in general payments reported to CMS, 2019-2025
14 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2021: $155 · 2022: $308 · 2023: $290 · 2024: $611 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $487.51 | 2019-2024 | Tri-Luma |
| Incyte Corporation | $249.53 | 2021-2025 | |
| Kerecis Limited | $246.49 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $175.23 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $153.07 | 2022-2025 | Sotyktu |
| Botanix Sb INC | $129.11 | 2025 | Sofdra |
| Leo Pharma INC. | $124.85 | 2024 | Adbry |
| Dermavant Sciences, INC. | $121.57 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $65.52 | 2022 | |
| Organogenesis INC. | $52.86 | 2022-2023 | Puraply |
| Ucb, INC. | $20.66 | 2024 | Bimzelx |
| Genzyme Corporation | $15.81 | 2024 | |
| Smith+Nephew, INC. | $15.61 | 2025 | Grafix Pl |
| Strata Skin Sciences, INC. | $6.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Beehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.